LITFULO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, UK.

Active ingredients

The drug LITFULO contains one active pharmaceutical ingredient (API):

1	Ritlecitinib UNII EAG4T1459K - RITLECITINIB TOSYLATE
	Ritlecitinib irreversibly and selectively inhibits Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family by blocking the adenosine triphosphate (ATP) binding site. JAK3 and TEC family mediated signalling pathways are both involved in alopecia areata pathogenesis, although complete pathophysiology is still not understood.
	Read more about Ritlecitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LITFULO Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AF08		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3045844, 3045855, 3045866
FR	Base de données publique des médicaments	62624259
IT	Agenzia del Farmaco	050899018, 050899020, 050899032
LT	Valstybinė vaistų kontrolės tarnyba	1097725, 1097726, 1097727
US	FDA, National Drug Code	0069-0334, 63539-334